尽管在癌症治疗方面取得了积极进展,但BioAtla的利润率估计值却有所下降。 BioAtla's earnings beat estimates, yet its stock dropped despite positive progress on cancer treatments.

BioAtla是一家开发抗体癌症治疗的生物技术公司,每季度报告的收入比估计的每股0.8美元高出0.2美元,EPS为0.32美元。 BioAtla, a biotech firm developing antibody-based cancer treatments, reported quarterly earnings that beat estimates by $0.08 per share, with an EPS of ($0.32). 尽管收入令人意外,但公司股票跌至0.37美元。 Despite the positive earnings surprise, the company's stock fell to $0.37. BioAtla的铅产品Mecbotamab vedotin和ozuriftabmab vedotin正在第二阶段试验。 BioAtla's lead products, mecbotamab vedotin and ozuriftabmab vedotin, are in Phase II trials. 该公司的目标是通过有条件的活性生物平台实现癌症治疗革命。 The company aims to revolutionize cancer treatment with its conditionally active biologics platform.